Clolar: Not ALL or nothing

The Oncologic Drugs Advisory Committee's decision to recommend limiting approval of Ilex Oncology Inc.'s Clolar clofarabine to refractory or relapsed acute lymphocytic leukemia (ALL) in pediatric patients is not likely to prevent its use to treat children with acute myelogenous leukemia (AML).

ODAC voted 9-6 to recommend approval of the ALL indication, but 14-1 against approval for AML. ILXO (San Antonio, Texas) submitted separate single-arm Phase II studies to support the indications.

In the

Read the full 749 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE